NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) — Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company is pleased to announce a non-brokered private placement for gross proceeds of $1,402,125 (the…


Previous articleIssues of Patient Safety and Ethical Violations in Psychedelic Therapy
Next articleOpinions | The Psychedelic Community Takes Itself Too Seriously